# A Clinical Study of MIL93 in Solid Tumors.

> **NCT04671875** · PHASE1 · UNKNOWN · sponsor: **Beijing Mabworks Biotech Co., Ltd.** · enrollment: 228 (estimated)

## Conditions studied

- Advanced Malignancies

## Interventions

- **DRUG:** Recombinant Humanized Monoclonal Antibody MIL93

## Key facts

- **NCT ID:** NCT04671875
- **Lead sponsor:** Beijing Mabworks Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-21
- **Primary completion:** 2025-08
- **Final completion:** 2025-08
- **Target enrollment:** 228 (ESTIMATED)
- **Last updated:** 2024-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04671875

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04671875, "A Clinical Study of MIL93 in Solid Tumors.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04671875. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*